Last reviewed · How we verify

NCT05735067

The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients

Status unknown Last updated 19 December 2023
What this trial tests

trial testing Blood sample collection in Multiple Sclerosis in 138 participants. Status unknown.

Timeline
1 February 2022
Primary endpoint
1 May 2023
30 July 2025

Quick facts

Lead sponsorGerman University in Cairo
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment138
Start date1 February 2022
Primary completion1 May 2023
Estimated completion30 July 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

German University in Cairo

Who can join

Adults 18 to 50, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study aimed to investigate the effect of interferon beta 1a on the clinical and immunological parameters in Egyptian relapse-remitting multiple sclerosis patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood sample collection

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other German University in Cairo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05735067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing